Search Results

October 4, 2023

SPRAVATO® (esketamine) Demonstrates Superior Efficacy Compared to Quetiapine Extended-Release in Treatment-Resistant Major Depressive Disorder

Data Published in the Current Issue of New England Journal of Medicine.

October 3, 2023

Janssen to Highlight Latest Advances in Retina Portfolio at the European Society of Retina Specialists (EURETINA) 2023 Annual Meeting

Five abstracts to be presented, including new real-world research and data on Janssen’s investigational gene therapy JNJ-1887

Innovative Medicine

October 3, 2023

Janssen Enters into Agreement with Sanofi to Advance Potential First-In-Class Vaccine Program

Vaccine candidate is being evaluated in Phase 3 study for the prevention of invasive E. coli disease (IED) which affects nearly 10 million adults annually1

Global health equity

September 29, 2023

Johnson & Johnson Confirms Intent Not to Enforce Patents for SIRTURO® (bedaquiline) for the Treatment of Multidrug-Resistant Tuberculosis in 134 Low- and Middle-Income Countries

Company continues to be focused on addressing perceived barriers to access and refocusing global efforts on the most-pressing barrier to access: underdiagnosis of the disease. Decision builds on a decade of Company investments in collaborative efforts to help countries sustainably scale up access and bring people living with multidrug-resistant tuberculosis (MDR-TB) into treatment.

Innovative Medicine

September 27, 2023

Janssen Demonstrates Commitment to Transform the Treatment of Multiple Myeloma through Innovative Science and Industry-Leading Portfolio with Largest-Ever Presence at 20th International Myeloma Society Annual Meeting

Presentations to highlight latest data across biologic, bispecific and CAR-T therapies with added insights from Global Multiple Myeloma Call-to-Action

Innovative Medicine

September 6, 2023

Janssen Announces Update to Phase 3 MACiTEPH Study Evaluating Macitentan 75mg in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Innovative Medicine

September 6, 2023

Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy With and Without Lazertinib versus Chemotherapy Alone in Patients with EGFR-Mutated Non-Small Cell Lung Cancer after Disease Progression on Osimertinib

MARIPOSA-2 is the first Phase 3 study to show statistically significant and clinically meaningful improvement in progression-free survival (PFS) in the post-osimertinib setting MARIPOSA-2 is the second RYBREVANT® Phase 3 study to show the potential to improve outcomes in patients with EGFR-mutated non-small cell lung cancer (NSCLC)

Innovative Medicine

August 28, 2023

Janssen Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of BALVERSA® (erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations

Submission Based on Confirmatory Data from Cohort 1 of the Phase 3 THOR Study, Which Showed a 36 Percent Reduction in the Risk of Death in Patients Treated with BALVERSA® Versus Chemotherapy

Innovative Medicine

August 25, 2023

Janssen Submits Supplemental Biologics License Application to the U.S. Food and Drug Administration Seeking Approval of RYBREVANT® (amivantamab-vmjw) in Combination with Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer

Application is supported by data from PAPILLON, the first randomized Phase 3 study to show clinically meaningful results in patients with NSCLC with EGFR exon 20 insertion mutations

Innovative Medicine

August 22, 2023

European Commission Approves TALVEY®▼ (talquetamab), Janssen’s Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Talquetamab, the first bispecific antibody targeting GPRC5D, showed an overall response rate of more than 70 percent with durable responses, including responses achieved by over 60 percent of patients with prior T-cell redirection therapy.1,2

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine